Complete financial analysis of Progyny, Inc. (PGNY) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Progyny, Inc., a leading company in the Medical – Healthcare Information Services industry within the Healthcare sector.
You may be interested
- Quipt Home Medical Corp. (QIPT.V) Income Statement Analysis – Financial Results
- Princeton National Bancorp, Inc. (PNBC) Income Statement Analysis – Financial Results
- Onion Global Limited (OGBLY) Income Statement Analysis – Financial Results
- Strat Petroleum, Ltd. (SPRL) Income Statement Analysis – Financial Results
- Brisa Bridgestone Sabanci Lastik Sanayi ve Ticaret A.S. (BRISA.IS) Income Statement Analysis – Financial Results
Progyny, Inc. (PGNY)
Industry: Medical - Healthcare Information Services
Sector: Healthcare
Website: https://www.progyny.com
About Progyny, Inc.
Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions for employers in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment. In addition, it provides surrogacy and adoption reimbursement programs for employers. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 1.09B | 786.91M | 500.62M | 344.86M | 229.68M | 105.40M | 48.58M |
| Cost of Revenue | 849.80M | 619.59M | 388.49M | 274.80M | 184.18M | 85.97M | 41.18M |
| Gross Profit | 238.80M | 167.33M | 112.14M | 70.06M | 45.51M | 19.43M | 7.40M |
| Gross Profit Ratio | 21.94% | 21.26% | 22.40% | 20.32% | 19.81% | 18.44% | 15.23% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 117.13M | 98.33M | 59.62M | 46.71M | 23.93M | 15.60M | 14.15M |
| Selling & Marketing | 59.49M | 45.66M | 20.18M | 15.01M | 11.90M | 7.29M | 4.26M |
| SG&A | 176.62M | 143.98M | 79.80M | 61.71M | 35.83M | 22.89M | 18.41M |
| Other Expenses | 0.00 | 286.00K | -366.00K | 210.00K | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 176.62M | 143.98M | 79.80M | 61.71M | 35.83M | 22.89M | 18.41M |
| Cost & Expenses | 1.03B | 763.57M | 468.28M | 336.51M | 220.01M | 108.85M | 59.59M |
| Interest Income | 0.00 | 814.00K | 461.00K | 121.00K | 58.00K | 0.00 | 0.00 |
| Interest Expense | 0.00 | 814.00K | 461.00K | 121.00K | 58.00K | 0.00 | 0.00 |
| Depreciation & Amortization | 2.28M | 1.60M | 1.30M | 1.91M | 2.13M | 1.88M | 1.56M |
| EBITDA | 64.47M | 24.94M | 33.64M | 10.25M | 11.81M | -1.57M | -9.45M |
| EBITDA Ratio | 5.92% | 3.17% | 6.72% | 2.97% | 13.06% | 1.30% | -17.97% |
| Operating Income | 62.18M | 23.34M | 32.34M | 8.35M | 27.85M | -3.45M | -11.01M |
| Operating Income Ratio | 5.71% | 2.97% | 6.46% | 2.42% | 12.13% | -3.28% | -22.65% |
| Total Other Income/Expenses | 8.51M | 1.10M | 95.00K | 331.00K | -18.23M | -3.44M | -1.45M |
| Income Before Tax | 70.69M | 24.44M | 32.44M | 8.68M | -8.56M | -6.89M | -12.46M |
| Income Before Tax Ratio | 6.49% | 3.11% | 6.48% | 2.52% | -3.73% | -6.54% | -25.64% |
| Income Tax Expense | 8.65M | -5.92M | -33.33M | -37.78M | 12.00K | -1.78M | -3.00K |
| Net Income | 62.04M | 30.36M | 65.77M | 46.46M | -8.57M | 661.00K | -12.45M |
| Net Income Ratio | 5.70% | 3.86% | 13.14% | 13.47% | -3.73% | 0.63% | -25.63% |
| EPS | 0.65 | 0.33 | 0.74 | 0.54 | -0.10 | 0.01 | -0.18 |
| EPS Diluted | 0.62 | 0.30 | 0.66 | 0.47 | -0.10 | 0.01 | -0.15 |
| Weighted Avg Shares Out | 95.02M | 92.20M | 89.11M | 85.72M | 83.57M | 81.56M | 70.59M |
| Weighted Avg Shares Out (Dil) | 100.67M | 99.96M | 100.36M | 99.06M | 83.57M | 81.56M | 81.56M |
Progyny (PGNY) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Progyny (PGNY) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Progyny (PGNY) Beats Q2 Earnings Estimates
Progyny (PGNY) came out with quarterly earnings of $0.43 per share, beating the Zacks Consensus Estimate of $0.36 per share. This compares to earnings of $0.15 per share a year ago.
Progyny, Inc. Announces Second Quarter 2024 Results
Achieves Record Quarterly Adjusted EBITDA, Strong Cash Flow Conversion RateBoard Authorizes Repurchase of $100 Million of Common Stock
Progyny (PGNY) Reports Next Week: Wall Street Expects Earnings Growth
Progyny (PGNY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Assisted Reproductive Technology Market Report 2024-2033: Vitrolife Leads the Competition with 9.8% Share, Followed by Ferring, and Progyny
Dublin, July 12, 2024 (GLOBE NEWSWIRE) -- The "Assisted Reproductive Technology Global Market Opportunities and Strategies to 2033" report has been added to ResearchAndMarkets.com's offering. The global assisted reproductive technology market reached a value of nearly $37.6 billion in 2023,...
Progyny, Inc. to Host 2024 Inaugural Investor Day
NEW YORK, June 26, 2024 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a transformative fertility, family building, and women's health benefits solution, today announced that it will host its inaugural Investor Day in New York City on Monday, August 12,...
Progyny, Inc. Announces Enhanced Global Services with Acquisition of Apryl
NEW YORK, June 24, 2024 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a transformative fertility, family building, and women's health benefits solution, today announced an expansion of its global offering with the acquisition of Apryl, a Berlin-based fertility benefits platform...
Fertility Pioneer and Kindbody Founder Gina Bartasi Returns as CEO to Lead Company's Next Phase of Growth
Kindbody is the Largest Women-founded, Women-led Fertility Company Serving Employers and Families through its National Clinic Network and Proprietary Technology Platform NEW YORK, June 11, 2024 /PRNewswire/ -- Kindbody , the leading national fertility clinic network and global family-building benefits...
Progyny: At This Price, Secular Tailwinds Are Too Compelling To Ignore
Progyny finds itself in an industry enjoying numerous secular tailwinds that they are well-positioned to capitalize on. The company reported Q1'24 on the 9th of May, with the stock plummeting around 15% after reporting a revenue miss. This presents an...
Progyny, Inc. to Present at Jefferies Global Healthcare Conference
NEW YORK, June 04, 2024 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a transformative fertility, family building, and women's health benefits solution, today announced that Pete Anevski, Progyny's Chief Executive Officer, will participate in a fireside chat at the Jefferies...
Source: https://incomestatements.info
Category: Stock Reports